Treatment of depression in patients with coronary artery disease [5]

JAMA

Volumn 297, Issue 17, 2007, Pages 1879-1880

  Dornelas, Ellen A ^a   Burg, Matthew M ^b  

^a HARTFORD HOSPITAL   (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HUMAN; INTERMETHOD COMPARISON; LETTER; MAJOR DEPRESSION; MEDICAL RESEARCH; MENTAL STRESS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOTHERAPIST; PSYCHOTHERAPY; RECURRENT DISEASE; TREATMENT OUTCOME; CORONARY ARTERY ATHEROSCLEROSIS; NOTE; PSYCHOLOGICAL ASPECT;

CITALOPRAM; CORONARY ARTERIOSCLEROSIS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHOTHERAPY, BRIEF; SEROTONIN UPTAKE INHIBITORS;

EID: 34247869696     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.17.1879     Document Type: Letter

References (5)

1. Lespérance F, Frasure-Smith N, Koszycki D, et al; CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297:367-379.
2. Hirschfield RM, Schatzberg AF. Long-term management of depression. Am J Med. 1994;97(suppl 6A):33s-38s.
3. Miller IW, Keitner GI. Combined medication and psychotherapy in the treatment of chronic mood disorders. Psychiatr Clin North Am. 1996;19:151-171.
4. Unützer J, Katon W, Callahan CM, et al; IMPACT Investigators. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288:2836-2845.
5. Iacoviello BM, McCarthy KS, Barrett MS, Rynn M, Gallop R, Barber JP. Treatment preferences affect the therapeutic alliance: implications for randomized controlled trials. J Consult Clin Psychol. 2007;75:194-198.